KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2016 - 2020)

Historic Non-Current Deffered Revenue for Nektar Therapeutics (NKTR) over the last 11 years, with Q4 2020 value amounting to $2.5 million.

  • Nektar Therapeutics' Non-Current Deffered Revenue fell 352.39% to $2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $2.5 million, marking a year-over-year decrease of 352.39%. This contributed to the annual value of $2.5 million for FY2020, which is 352.39% down from last year.
  • Nektar Therapeutics' Non-Current Deffered Revenue amounted to $2.5 million in Q4 2020, which was down 352.39% from $2.5 million recorded in Q3 2020.
  • In the past 5 years, Nektar Therapeutics' Non-Current Deffered Revenue registered a high of $60.1 million during Q2 2016, and its lowest value of $2.5 million during Q4 2020.
  • Its 5-year average for Non-Current Deffered Revenue is $24.5 million, with a median of $12.1 million in 2018.
  • Per our database at Business Quant, Nektar Therapeutics' Non-Current Deffered Revenue tumbled by 151.17% in 2017 and then tumbled by 7970.65% in 2018.
  • Over the past 5 years, Nektar Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $51.9 million in 2016, then tumbled by 63.34% to $19.0 million in 2017, then crashed by 43.52% to $10.7 million in 2018, then crashed by 76.23% to $2.6 million in 2019, then fell by 3.52% to $2.5 million in 2020.
  • Its last three reported values are $2.5 million in Q4 2020, $2.5 million for Q3 2020, and $2.5 million during Q2 2020.